Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition and Contractual Adjustments - Contract Assets and Liabilities (Details)

v3.10.0.1
Revenue Recognition and Contractual Adjustments - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract asset $ 400 $ 541
Long-term pharma contract asset 29 31
Total pharma contract asset 429 572
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 264 371
Long-term pharma capitalized commissions 574 171
Total pharma capitalized commissions 838 542
Contract with Customer, Liability [Abstract]    
Current pharma contract liability 2,155 1,406
Long-term pharma contract liability 648 283
Total pharma contract liability $ 2,803 $ 1,689